Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that ZD1839 (Iressa), an anticancer drug, was associated with acneiform eruptions and hair growth abnormalities due to its inhibition of epidermal growth factor receptor signaling in the skin.

This study reports that Iressa, an anti-cancer agent, commonly causes acneiform eruptions and xerosis as cutaneous side effects, similar to other agents targeting epidermal growth factor receptors.

In a reported case, the use of ZD1839 (Iressa), an EGFR tyrosine kinase inhibitor, resulted in hair changes and acneiform eruptions as cutaneous side effects.

This study found that co-administering sasam-Kyeongokgo with gefitinib enhanced gefitinib's anti-tumor activity and exhibited favorable anti-cachexia effects in mice with non-small-cell lung cancer.

This review details the skin and hematological toxicities of tyrosine kinase inhibitors like erlotinib, gefitinib, and imatinib, and highlights ongoing concerns about cardiac toxicity, reporting no new clinical findings.

This case report describes a woman who developed extensive nonscarring inflammatory hair loss after two years of gefitinib treatment, highlighting potential cutaneous side effects associated with epidermal growth factor receptor blockers.

This study discusses two cases of acneiform skin eruptions associated with the use of the EGFR inhibitor ZD1839 in prostate cancer treatment, emphasizing the need for dermatologists to be aware of potential skin reactions.

This study found that individuals with alopecia areata experience variations in cortisol and insulin levels and adaptive mechanism pressures, which may serve as potential therapeutic targets.

This study introduces diagnostic and therapeutic algorithms tailored for tailored management of alopecia areata based on patient-specific factors like age, disease severity, and quality of life.

This study found that low-dose dutasteride is effective and safe for treating male androgenetic alopecia, showing significant improvement in hair growth and reduction in hair shedding in most patients.

This article provides a review of alopecia areata, highlighting the development of diagnostic and therapeutic algorithms that consider factors such as age, disease severity, and quality of life, but it reports no new clinical findings.

The document's conclusion cannot be provided because the content is not available for analysis.

In this review, researchers highlight recent findings on the cosmeceutical applications of phlorotannins from brown seaweeds, emphasizing their promising bioactive properties since 2020.

This case study reported that a 74-year-old woman with metastatic rectal cancer experienced temporary trichomegaly, or eyelash lengthening, associated with cetuximab treatment, which resolved after discontinuation of the drug.

This review describes the approved use and adverse effects of gefitinib in patients with advanced non-small cell lung cancer, without presenting new clinical findings.

Skin problems like acne, dry skin, and nail and hair changes are common in patients taking EGFR inhibitors.

This review discusses the cutaneous side effects of chemotherapy, noting that they frequently involve changes to skin, hair, and nails, and reports no new results.

This study conducted molecular docking and ADME property analysis on 144 newly designed isatin analogs, suggesting they exhibit lead-like properties for targeting EGFR enzymes.

This review discusses skin-related toxicities associated with targeted cancer therapies and emphasizes the need for dermatologists to understand and manage these adverse effects, but reports no new experimental results.

This study mapped the safety profile of EGFR-TKIs by analyzing FDA adverse event reports, highlighting unexpected reactions like intestinal obstruction and hypokalaemia with gefitinib and erlotinib.

This review discusses the skin side effects associated with targeted cancer therapies and reports no new clinical results; it emphasizes the need for empirical management based on expert opinion.

This review addresses the role of skin-resident adult stem/progenitor cells in skin homeostasis, disease, and cancer development, and reports no new research results.

This study reported that the most common skin side effect of epidermal growth factor receptor inhibitors was a papulopustular rash, treatable with symptom-targeted therapies, while drug suspension was rarely needed.

This article reviews eyelash elongation as a side effect of EGFR inhibitors in cancer treatment, finding that the condition is typically not severe and may be managed by trimming.

This review outlines various non-rash skin toxicities associated with novel targeted anticancer therapies and provides guidelines for their early diagnosis and management, but reports no new clinical results.

This review summarizes the anticarcinogenic, anti-inflammatory, and other health effects of green tea, noting its historical and ongoing use in dermatological and cosmeceutical applications, but reports no new clinical results.

This article reviews the cutaneous reactions and characteristic skin changes associated with chemotherapy, radiation therapy, and new targeted cancer treatments, reporting no new clinical results.

This review discusses the adverse skin effects of EGFR inhibitors used in cancer treatment, exploring their mechanisms and offering strategies for prevention and management, but reports no new experimental findings.

This study constructed a panel of pharmacokinetic and pharmacodynamic genes, revealing that current SNP chips insufficiently capture many drug-response gene variants, highlighting the need for complementary genetic approaches.

This case report describes a patient with non-small cell lung cancer who experienced trichomegaly (excessive eyelash growth) as a side effect of erlotinib treatment without developing typical skin rash.